Zurich Cantonal Bank
GLUE icon

Zurich Cantonal Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Zurich Cantonal Bank’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
79,122
+63,868
+419% +$1.21M ﹤0.01% 1164
2026
Q1 		$251K Buy
15,254
+14,200
+1,347% +$272K ﹤0.01% 2167
2025
Q4 		$16.5K Hold
1,054
– – ﹤0.01% 2471
2025
Q3 		$7.81K Sell
1,054
-506
-32% -$2.68K ﹤0.01% 2509
2025
Q2 		$7.04K Sell
1,560
-293
-16% -$1.31K ﹤0.01% 2526
2025
Q1 		$8.6K Buy
+1,853
New +$11.4K ﹤0.01% 2597

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Zurich Cantonal Bank's GLUE Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Monte Rosa Therapeutics (GLUE) stake by 419% in Q2 2026, buying an estimated $1.21M and bringing the position to 79,122 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1164.

Zurich Cantonal Bank first reported a position in GLUE in Q1 2025 and has held it in 6 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Zurich Cantonal Bank held 79,122 shares of Monte Rosa Therapeutics worth $1.91M as of Q2 2026.
  • Zurich Cantonal Bank bought 63,868 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.21M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1164 holding.
  • Zurich Cantonal Bank first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.